Navidea Biopharmaceuticals Inc (NAVB)

[Fenix1357]

In addition to establishing the clinical effectiveness of the indication, the Pharmalucence study consolidated information regarding SCI preparation parameters including injection volume and radioactive dose as well as describing performance stratified by injection site. Safety data related to the subcutaneous injection route were also collected. Related recommendations are included in updated drug labeling.

This may have nothing to do with NEOP.

Another angle to consider is whether Pharmalucence has established FDA approval only for its own proprietary brand of sulfur colloid so as to establish market exclusivity for its own brand of sulfur colloid. A similar story happened with another medicine used in Obstetrics and once the co. got FDA exclusivity raised its price several fold.